Serum gastrin concentration in neonates with early-onset severe infections

Stojewska, Małgorzata; Oświęcimska, Joanna; Stachurska, Aneta; Szymańska, Anna; Staśkiewicz, Katarzyna; Godula‐Stuglik, Urszula

doi:10.18544/ep-01.16.02.1667

Cited by 1 publication

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, recent studies have led to the definition of P-SEP cut-off values for healthy term and preterm neonates in the first three days of life, favoring early identification of neonates with EOS [191]. Table 4 summarizes the main studies on the accuracy of presepsin for the diagnosis of neonatal sepsis [192][193][194][195][196][197][198][199][200][201]. Starting from these findings, P-SEP is presently considered a promising biomarker for the diagnosis of EOS.…”

Section: Presepsinmentioning

confidence: 99%

Biomarkers of Neonatal Sepsis: Where We Are and Where We Are Going

Boscarino,

Migliorino,

Carbone

et al. 2023

Antibiotics

View full text Add to dashboard Cite

Neonatal sepsis is a bacterial bloodstream infection leading to severe clinical manifestations frequently associated with death or irreversible long-term deficits. Antibiotics are the drug of choice to treat sepsis, regardless of age. In neonates, the lack of reliable criteria for a definite diagnosis and the supposition that an early antibiotic administration could reduce sepsis development in children at risk have led to a relevant antibiotic overuse for both prevention and therapy. The availability of biomarkers of neonatal sepsis that could alert the physician to an early diagnosis of neonatal sepsis could improve the short and long-term outcomes of true sepsis cases and reduce the indiscriminate and deleterious use of preventive antibiotics. The main aim of this narrative review is to summarize the main results in this regard and to detail the accuracy of currently used biomarkers for the early diagnosis of neonatal sepsis. Literature analysis showed that, despite intense research, the diagnosis of neonatal sepsis and the conduct of antibiotic therapy cannot be at present decided on the basis of a single biomarker. Given the importance of the problem and the need to reduce the abuse of antibiotics, further studies are urgently required. However, instead of looking for new biomarkers, it seems easier and more productive to test combinations of two or more of the presently available biomarkers. Moreover, studies based on omics technologies should be strongly boosted. However, while waiting for new information, the use of the clinical scores prepared by some scientific institutions could be suggested. Based on maternal risk factors and infant clinical indicators, sepsis risk can be calculated, and a significant reduction in antibiotic consumption can be obtained.

show abstract